WNT PATHWAY TUMOUR SUPPRESSOR - Med Uni Graz

WNT PATHWAY TUMOUR SUPPRESSOR - Med Uni Graz

Doctoral College Metabolic & Cardiovascular Disease WNT PATHWAY TUMOUR SUPPRESSOR MUTATIONS IN CANCER: BEYOND LOSS-OF-FUNCTION? GUEST LECTURE by Pro...

446KB Sizes 0 Downloads 8 Views

Doctoral College Metabolic & Cardiovascular Disease

WNT PATHWAY TUMOUR SUPPRESSOR MUTATIONS IN CANCER: BEYOND LOSS-OF-FUNCTION? GUEST LECTURE by

Prof. Madelon Maurice, PhD Department of Cell Biology, Center for Molecular Medicine, University Medical Center Utrecht, The Netherlands

Tuesday, 25.04.2017 17:00 SR 07.11, Preclinics, MUG (Harrachgasse 21, 1st floor)

Canonical

Non-canonical PCPWNT signaling Consonni et al. (2014) Nat Rev Mol Cell Biol 15:357-62

Strong proliferation of the Rnf43 Znrf3 compound mutant intestine is accompanied by Wnt/β-catenin activation as well as stem cell and Paneth cell metaplasia. Koo et al. (2012) Nature 488(7413):665-9

In vivo temperature-dependent hyperplastic growth induced by Drosophila Axin cancer mutants is rescued by aggregon mutations. Anvarian et al. (2016) Nat Struct Mol Biol 23(4):324-32

Model for the mechanism of action of Axin RGS cancer variants. Anvarian et al. (2016) Nat Struct Mol Biol 23(4):324-32

Small-sized β-catenin complexes mark Wnt pathway activation in primary human tumor cells. Gerlach et al. (2014) Open Biol 4:140120

Cell proliferation influences Wnt3 surface level and signaling range. Farin et al. (2016) Nature 530:340-3

Wnt-induced β-catenin phosphorylation within the destruction complex is confirmed in primary tissues. Li et al. (2012) Cell 149:1245-56